{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:30:49Z","timestamp":1768530649797,"version":"3.49.0"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,12,15]],"date-time":"2015-12-15T00:00:00Z","timestamp":1450137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The aim of the study was to analyze the interaction between celecoxib and low dose aspirin for COX\u20101 binding and its consequences on the aspirin\u2010mediated antiplatelet effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We investigated <jats:italic>ex vivo<\/jats:italic> the interaction between celecoxib and aspirin for COX\u20101 binding and measured the resulting antiplatelet effects. We applied mechanism\u2010based pharmacokinetic\u2212pharmacodynamic (PKPD) modelling to analyze these data and to predict <jats:italic>in vivo<\/jats:italic> platelet aggregation for different doses and administration schedules of aspirin and celecoxib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The predictions of the PK\u2010PD model were consistent with results from previous studies that investigated interaction between aspirin and celecoxib. The modelling results indicate that celecoxib can attenuate to a limited extent the <jats:italic>in vivo<\/jats:italic> antiplatelet effects of low dose aspirin. The extent of this interaction can be substantial (up to 15% increase in platelet aggregation by 200\u00a0mg\u00a0day<jats:sup>\u22121<\/jats:sup> celecoxib when combined with low dose aspirin) during the first days of aspirin administration in patients who are already treated with celecoxib, and it cannot be prevented by separate administration of the interacting drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>At the recommended therapeutic doses, celecoxib can attenuate to a limited extent the <jats:italic>in vivo<\/jats:italic> antiplatelet effects of low dose aspirin. Patients receiving a combination of low dose aspirin and the recommended doses of celecoxib were not identified to have increased risk of cardiovascular and cerebrovascular events due to competition between these drugs for COX\u20101 binding. Interaction between low dose aspirin and other COX\u20102 inhibitors and its clinical consequences requires further investigation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.12801","type":"journal-article","created":{"date-parts":[[2015,10,12]],"date-time":"2015-10-12T22:18:03Z","timestamp":1444688283000},"page":"316-326","source":"Crossref","is-referenced-by-count":8,"title":["Celecoxib interferes to a limited extent with aspirin\u2010mediated inhibition of platelets aggregation"],"prefix":"10.1111","volume":"81","author":[{"given":"Mark","family":"Ruzov","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences Ben\u2010Gurion University of the Negev  Beer Sheva"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilad","family":"Rimon","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences Ben\u2010Gurion University of the Negev  Beer Sheva"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg","family":"Pikovsky","sequence":"additional","affiliation":[{"name":"Blood Bank &amp; Hematology Institute Soroka University Medical Center  Beer Sheva Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Stepensky","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences Ben\u2010Gurion University of the Negev  Beer Sheva"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,12,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa003199"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2293"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.05.004"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.11.054"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847020-00006"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2008.10.015"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph3072059"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2011.01313.x"},{"key":"e_1_2_9_10_1","unstructured":"FDA. Information for Healthcare Professionals: Concomitant Use of Ibuprofen and Aspirin.2006.http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm125222.htm. Accessed onJune30 2015."},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127000204200910"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/hc3301.092790"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0909765106"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.027102"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.1.180.180"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0672"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.10.047"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(95)93881-Y"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2006.06.037"},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1160\/TH09-04-0215","article-title":"Utility of 96\u2010well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness","volume":"102","author":"Armstrong PC","year":"2009","journal-title":"Thromb Haemos"},{"key":"e_1_2_9_21_1","unstructured":"Arachidonic Acid reagent leaflet Catalogue No. 5364 Helena Laboratories Beaumont TX USA."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1309\/Y9EC63RW3XG1V313"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2014.971010"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01958.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03133.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp097"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59291"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04723.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.181404"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22169"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-04-0216"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.110.960187"},{"key":"e_1_2_9_33_1","article-title":"Randomized controlled trial comparing impact on platelet reactivity of twice\u2010daily with once\u2010daily aspirin in people with type two diabetes","author":"Bethel MA","year":"2015","journal-title":"Diabet Med"},{"key":"e_1_2_9_34_1","unstructured":"CELEBREX\u00ae (celecoxib) prescribing information FDA January2011."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1984.tb06115.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12801","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:56:43Z","timestamp":1696327003000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,15]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1111\/bcp.12801"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12801","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,15]]}}}